Investor Dashboard
Developing two novel drugs to improving the lives of people with neurodevelopmental disabilities, with potential for first US marketing approval in Q1 2023.
Subscribe to our Email Alerts
Sign up to our email alerts to get the latest news and updates delivered directly in your inbox.
